Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid Treatment of dermatomyositis Withdrawn

Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid Treatment of dermatomyositis Withdrawn

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2070https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2070
Retrieved on: 
Mardi, avril 9, 2024
Information
Tags: 
Eurostat, Civil service commission, Eating, Diagnosis, Azathioprine, Disease, Dermatomyositis, Risk, Rash, Inflammation, Patient, Committee, Knowledge, Tissue, Regulation, EMA, IRIS, Mouth, European, Skin, COMP, Heart, Sponsor, European Commission, Immune system, Safety, Muscle weakness, Skeletal muscle, Stomach, Marketing, Medicine, Pharmaceutical industry
Geotags: 
EUROPEAN UNION, RARE, EC, SWEDEN, ICELAND, EU, NORWAY, HUNGARY, LIECHTENSTEIN
Résumé
Key Points: 


Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid Treatment of dermatomyositis Withdrawn

Copyright: 
2024 European Medicines Agency. All Rights Reserved.